Arbutus’ Hepatitis B Candidate Shows Encouraging Antiviral Activity
Arbutus Biopharma Corporation (NASDAQ:ABUS) has announced preliminary data from its Phase 1a/1b trial of AB-836, an oral hepatitis B virus (HBV)…
Why Arbutus Shares Are Soaring Today
Arbutus Biopharma Corp (NASDAQ: ABUS) is soaring Wednesday after The Patent Trial and Appeals Board turned down Moderna Inc's (NASDAQ: MRNA) appeal to invalidate two of Arbutus' patents on drug-de
Mid-Day Market Update: Build-A-Bear Jumps After Q3 Results; BeyondSpring Shares Slide
Midway through trading Wednesday, the Dow traded up 1.06% to 34,847.76 while the NASDAQ climbed 1.17% to 15,719.00. The S&P also rose, gaining 1.48% to 4,634.64.
Arbutus Reports Prelim. Data On Co.’s Capsid Inhibitor AB-836 Is Generally Safe, Well Tolerated, Provides Antiviral Activity
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to
Arbutus Shares Are Soaring As Moderna Loses Appeal Of Board Ruling On COVID-19 Vaccine Delivery Technology Patent
Shares of small-cap biotech Arbutus Biopharma Corporation (NASDAQ: ABUS) are advancing strongly on above-average volume on Wednesday.
JMP Securities Maintains Market Outperform on Arbutus Biopharma, Raises Price Target to $9
JMP Securities analyst Jason Butler maintains Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform and raises the price target from $7 to $9.
Arbutus Biopharma Q3 EPS $(0.24), Inline, Sales $3.34M Beat $2.38M Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. This is a 11.11 percent increase over losses of $(0.27) per share from the same period last year.
Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.